Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle.
We developed a drug-free regional intravenous (r.i.) delivery protocol of recombinant adeno-associated virus (rAAV) 1 and 8 to an entire limb in the nonhuman primate (NHP), and compared the results with those produced by intramuscular (i.m.) delivery of the same dose of vector. We show that r.i. delivery of both serotypes was remarkably well tolerated with no adverse side-effects. After i.m., muscle transduction was restricted to the site of injection with a high number of vector copies per cell for rAAV1. In contrast, although r.i. delivery resulted in a lower vector copy per cell, it was detectable in the vast majority of muscles of the injected limb. The amounts of circulating infectious rAAV were similar for both serotypes and modes of delivery. At autopsy at up to 34 months after vector administration, similar biodistribution patterns were found for both vectors and for both modes of delivery, with numerous organs found to be positive for vector sequence when assayed using PCR and Southern blot. Altogether, we demonstrated that r.i. is a simple and efficient transduction protocol in NHPs, resulting in higher expression of the transgene with a lower number of vector genomes per cell. However, regardless of the mode of delivery, concerns continue to be raised by the presence of vector sequences detected at distant sites.
Toromanoff
Alice
A
INSERM UMR 649, CHU Nantes, Faculté de Médecine, Université de Nantes, Nantes, France.
Chérel
Yan
Y
Guilbaud
Mickaël
M
Penaud-Budloo
Magalie
M
Snyder
Richard O
RO
Haskins
Mark E
ME
Deschamps
Jack-Yves
JY
Guigand
Lydie
L
Podevin
Guillaume
G
Arruda
Valder R
VR
High
Katherine A
KA
Stedman
Hansell H
HH
Rolling
Fabienne
F
Anegon
Ignacio
I
Moullier
Philippe
P
Le Guiner
Caroline
C
D000818:Animals; D004279:DNA, Viral / Q000097:blood; D000229:Dependovirus; D015870:Gene Expression; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D007273:Injections, Intramuscular / Q000009:adverse effects; D007275:Injections, Intravenous / Q000009:adverse effects; D008252:Macaca fascicularis; D008297:Male; D018482:Muscle, Skeletal; D014161:Transduction, Genetic / Q000379:methods*; D019076:Transgenes
D004279:DNA, Viral